Provided by Tiger Trade Technology Pte. Ltd.

Natera

341.79
+12.863.91%
Post-market: 342.991.20+0.35%19:51 EDT
Volume:1.04M
Turnover:351.00M
Market Cap:48.95B
PE:-248.96
High:343.00
Open:327.91
Low:327.15
Close:328.93
52wk High:343.18
52wk Low:157.43
Shares:143.22M
Float Shares:139.00M
Volume Ratio:1.14
T/O Rate:0.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3729
EPS(LYR):-1.5269
ROE:-12.54%
ROA:-8.08%
PB:26.87
PE(LYR):-223.85

Loading ...

Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of Apg-157 in Head and Neck Cancer

THOMSON REUTERS
·
Jun 29

Natera - Phase 3 Trial Expected to Begin Enrollment in Second Half of 2026

THOMSON REUTERS
·
Jun 29

Natera Director Herm Rosenman Disposes of 16,530 Shares for $4.13 Million

Reuters
·
Jun 27

Natera Price Target Announced at $310.00/share by Bernstein

Dow Jones
·
Jun 26

Natera Inc : Bernstein Resumes Coverage with Outperform Rating; Price Target $310

THOMSON REUTERS
·
Jun 26

Natera Partners with Eledon to Supply Prospera Monitoring for Planned Phase 3 Kidney Transplant Trial

Reuters
·
Jun 25

Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial

THOMSON REUTERS
·
Jun 25

Natera - Eledon to Initiate Phase 3 Kidney Transplant Trial in Late 2026

THOMSON REUTERS
·
Jun 25

Movement Alert|Natera Rises 9.14% in Regular Trading, Signatera MRD Test Secures Regulatory Approval in Japan

Market Focus
·
Jun 25

Street View: Japan Nod for Natera's Cancer Test Meaningful, but Payoff Seen Later

Reuters
·
Jun 24

Sector Update: Healthcare Stocks Rise Pre-Bell Wednesday

MT Newswires Live
·
Jun 24

Natera : Barclays Cuts Target Price to $260 from $280

THOMSON REUTERS
·
Jun 24

Natera announces Signatera receives regulatory approval in Japan

TIPRANKS
·
Jun 24

BRIEF-Natera Says Signatera Receives Regulatory Approval In Japan For Colorectal Cancer

Reuters
·
Jun 24

Natera Signatera colorectal cancer MRD test wins Japan PMDA approval

Reuters
·
Jun 24

Natera Inc - Natera Expects to Commercially Launch Signatera for Crc in Japan by End of 2026

THOMSON REUTERS
·
Jun 24

Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer

THOMSON REUTERS
·
Jun 24

Natera price target raised to $270 from $250 at BTIG

TIPRANKS
·
Jun 24

Natera Is Maintained at Buy by BTIG

Dow Jones
·
Jun 24

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as AI Spending Concerns Weigh on Technology Shares

MT Newswires Live
·
Jun 23